Aristotle University Of Thessaloniki (AUTH)
Διερεύνηση της έκφρασης μορίων του εξωκυττάριου χώρου σε ασθενείς με βλεννοπολυσακχαριδώσεις και νευροϊνωμάτωση τύπου Ι
Abstract
dc:descriptionThe aim of the present study was the assessment of the expression of various molecules of the Extracellular Matrix (ECM), such as matrix metalloproteinases (MMPs) and their tissue inhibitors (TIMPs), hyaluronic acid (HA) with the enzymes and receptors which are involved in its metabolism (HASs/HYALs/CD44/RHAMM), as well as some members of the proteoglycan family (PGs) in patients with Mucopolysaccharidoses (MPS) and Neurofibromatosis type I (NF1), with the goal to use those molecules as potential biomarkers for patients’ diagnosis and disease follow-up. Patients & Methods: The sample included 13 patients with MPSs (9 with MPS III, 3 with MPS II and 1 with MPS VI) and 45 patients with NF1, as well as an equal number of sex and age matched healthy subjects for the control group. Gelatinase activity (MMP-2, MMP-9) was measured with the use of gelatin zymography. The concentration of circulating ECM molecules was measured by ELISA, while their expression at the genetic level was assessed with the use of Real-Time RT-PCR. The enzyme activity of HYALs was measured with the use of hyaluronidase zymography. The levels of the studied molecules have been correlated with the presence of the NF1 diagnostic criteria and the results of the laboratory and radiological assessment. Results: MPSs MPS patients exchibited a statistically significant increase in the enzymatic activity and protein levels of MMP-2, while the same parameters have been decreased concerning MMP-9 expression. Following the initiation of enzyme replacement therapy, MMP-2 levels started decreasing and finally normalized after a 24 month period in MPS II patients. HA levels were significantly increased in all MPS types. In relation to PG expression, we detected an increase in the circulating levels of aggrecan, biglycan, decorin and syndecan-2, -3 and -4, while a reduction in the serum levels of syndecan-1 and versican was noted. Especially in the group of MPS III patients, circulating levels of syndecan-2 and decorin were significantly increased. NF1 NF1 patients had a statistically significant increase in the circulating levels of MMP-2, TIMP-1, TIMP-2 and MMP-9/TIMP-1. MMP-2 levels correlated with the age only in the patient group. No significant differences were found concerning the expression of HA and the enzymes/receptors which are involved in its metabolism. Syndecan-2, decorin and versican were increased in the serum of NF1 patients as well. Logistic regression analysis was performed to estimate the odds ratios (OR) of variables in the prediction of the presence of clinical/laboratory features of the disease. The increase of HA in the serum of patients increased significantly the risk of having UBOs in brain MRI. We also found that MMP-2 is positively associated with the presence of freckling. When patients were categorized based on their cognitive function, syndecan-3 and decorin were significantly increased in those who had mental retardation. Conclusions: The index study revealed the potential use of ECM molecules as biomarkers for MPSs and NF1. According to our results many of the studied molecules can be potentially used for the diagnosis and follow-up of patients suffering from the above mentioned disorders.
Degree
thesis:*- Grantor dc:publisher
- Aristotle University Of Thessaloniki (AUTH)
- Year dc:date
- 2015
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Batzios, Spyros
- Μπάτζιος, Σπύρος
Subjects
dc:subject × 12Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/35697